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Magnetic nanoparticles have been extensively investigated for in vivo nanomedical applications in the last
decade. PEG coating improves the solubility and stability of the nanoparticles, and provides stealth
properties by preventing opsonization and subsequent removal by the reticuloendothelial system. All
these eﬀects conferred by the PEG coating are dependent on its molecular weight. Therefore, the
selection of the right MW of PEG is a crucial point in the design of new nanomaterials for in vivo
applications. The aim of this work lies in the in vivo optimization of the circulation times of small iron
oxide nanoparticles by coating them with PEG of diﬀerent MWs. PEGylated small superparamagnetic iron
oxide nanoparticles (PEG-SPIONs), using PEG MWs ranging from 600 to 8000, were synthesized
following a ligand exchange methodology, resulting in highly stable and water-soluble nanoparticles.
Semi-quantitative and quantitative MRI studies allowed us to track the pharmacokinetics and
biodistribution of intravenously injected PEG-SPIONs (HD < 50 nm) in vivo up to one week. Results show
that high MW PEGs (6000–8000) lead to nanoparticle aggregation and low MW PEGs (#1500) are not
able to stabilize the 6 nm iron oxide nanoparticles in physiological medium or confer stealth properties,
thus leading to rapid recognition by the RES. In contrast, PEG3000-SPIONs show excellent in vivo
behavior, they do not aggregate and they exhibit better stealth properties, giving rise to slower liver
uptake and longer circulation times. In conclusion, 3000 Da turned out to be the optimal MW for the
PEGylation of small nanoparticles (6 nm) designed for biomedical applications in which long circulation
times together with moderate liver uptake are desirable.Introduction
Magnetic nanoparticles (MNPs) emerged as promising multi-
functional platforms for both drug delivery and imaging based
diagnostics.1–5 However, one of the major limitations of these
nanomaterials for in vivo applications is their distribution
within the body. Most of the nanomaterials injected intrave-
nously are rapidly sequestered by the reticuloendothelial system
(RES), thus reducing their eﬃcacy as diagnostic or therapeutic
agents.6 Many eﬀorts have been made to enhance blood circu-
lation times and reduce accumulation in the non-desired
tissues by modifying the physico-chemical characteristics of
the nanomaterial such as size, surface charge and hydrophilic/icine and Biotechnology, BIONAND (Junta
que Tecnolo´gico de Andaluc´ıa, Ma´laga,
cia@bionand.es
sity, Joseph Black Building, G12 8QQ, UK
ESI) available: Additional experimental
Ps, FTIR spectra, thermogravimetric
nd T2 parametric maps patterns of
g
hemistry 2015hydrophobic balance, which are directly involved in the in vivo
distribution.7–12 However, there is another important parameter
that has to be taken into account when designing nano-
materials for intravenous administration, the plasma protein
adsorption.13–15 It is known that neutral and negatively charged
nanomaterials reduce the adsorption of plasma protein thus
increasing blood circulation times,16 but in some cases the
surface charge of the material is not enough to avoid the protein
adsorption and the consequent clearance by RES. A polymer
layer on the nanomaterial could create a hydrophilic protective
coating that inhibits the opsonization process making them
stealth.17 The polymer has to be biocompatible and enhance the
solubility and stability of the nanomaterial. Among the diﬀerent
biocompatible polymers reported in the literature, polyethylene
glycol (PEG) has been the most commonly used.7,9,18–21 PEGy-
lated molecules have been attached directly to the nano-
materials or used as part of the ligand synthesis that will
functionalize the corresponding nanomaterial. In both cases,
the PEGylated nanomaterials present an improvement in their
solubility and stability in aqueous media given by steric repul-
sion between the PEG molecules. These parameters are also
inuenced by the molecular weight (MW) of the PEGylatedRSC Adv., 2015, 5, 76883–76891 | 76883
Fig. 1 Hydrodynamic diameters of PEG-SPIONs (100 mg mL1) vs.
time at 37 C in (A) water at pH 7.2; (B) PBS buﬀer at pH 7.2 and (C) cell
growth medium.
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View Article Onlinemolecule. For instance, some in vivo studies reported that
particles coated with high MW PEG (>5000 Da) and hydrody-
namic diameters between 50–150 nm presented longer circula-
tion times and a reduction of liver uptake.22–25 However, in vivo
information concerning the eﬀect of PEG on the pharmacoki-
netics and biodistribution of particles withHD sizes below 50 nm
is still rare. In this context, we report the synthesis and charac-
terization of a variety of PEGylated (PEG MW ¼ 600–8000 Da)
small iron oxide nanoparticles with high stability in diﬀerent
media and conditions. A detailed study of the in vivo pharma-
cokinetics of diﬀerent PEGylated nanoparticles has been con-
ducted in mice using MRI. Parametric MRI allowed us to
quantify over time the T2 changes induced by these SPIONs on
the main organs involved in the excretion process, namely, liver
and kidneys. Using these quantitative data we could follow and
compare the long-term pharmacokinetics of the diﬀerent iron
oxide nanoparticles and thus determine the eﬀect of PEG MW
and hydrodynamic size on their biodistribution and circulation
times. The information provided by this paper will allow the
readership to better understand the behaviour of functionalized
nanoparticles in vivo, which is a crucial aspect that needs to be
taken into account in the design of new nanomaterials for
biomedical applications.Fig. 2 Stability measurements of PEG-SPIONs (A) vs. temperature in
PBS buﬀer and (B) vs. pH in water. Cytotoxicity of the PEG-SPIONs by
the MTT assay of MG-63 cells treated for 24 h (C) and 72 h (D) at
diﬀerent concentrations.Results and discussion
Characterization of PEG-SPIONs
The stability of the nanoparticles depends on diﬀerent factors
such as pH and ionic strength of the medium. Therefore, the
diﬀerent MW PEG-SPIONs were transferred into physiological
conditions of pH 7.2 and NaCl 0.9%, resulting in black clear
solutions for all the PEG-SPIONs but the lowest MW, PEG600-
SPION, which collapsed due to the lack of stability in the
presence of salts. The soluble PEG-SPIONs exhibited hydrody-
namic sizes between 17 and 46 nm (Table 1). It was observed
that the PEGylation induced an over-increment of the hydro-
dynamic radius of the SPIONs with the higher molecular weight
PEGs (PEG6000- and PEG8000-SPIONs) with respect to the lower
ones (PEG1500- and PEG3000-SPIONs). This is likely due to the
fact that higher MWs induce aggregation of nanoparticles, with
the corresponding increase of the hydrodynamic diameter. This
eﬀect was also detected by transmission electron microscopy
(TEM). The TEM images of the PEG6000- and PEG8000-SPIONs
(see Fig. S1 in the ESI†) showed the presence of these small
aggregates of nanoparticles. On the contrary, monodisperseTable 1 Characterization of PEG-SPIONs
MNPs
Hydrodynamic
size (nm)
Packing density
(molecules per nm2) r
600 24  4 1.99 1
1500 17  1 1.31
3000 18  3 0.71 1
6000 44  2 0.25 1
8000 46  3 0.35 1
76884 | RSC Adv., 2015, 5, 76883–76891nanoparticles were observed in the TEM images of lower
molecular weight PEG (PEG600-, PEG1500- and PEG3000-
SPIONs). Nevertheless, all the PEG-SPIONs with diameters
ranging from 1500 to 8000 Da, remained stable over months in
physiological conditions. Zeta potential of the PEG-SPIONs
resulted to be negative charge at pH 7.2 (Table 1). Further
characterization, such as FTIR spectroscopy and thermo-
gravimetric analysis, were performed for all the nanoparticles.2 (mM
1 s1) 1.5 T r2 (mM
1 s1) 9.4 T
Zpotential
(meV)
49  30 63.7  0.4 18.1  3.1
90  1.4 113.6  1.1 19.8  1.1
03  11 151.1  1.7 19.3  0.9
90  1.6 253.6  5.5 14.4  0.2
80  3.2 254.2  7.0 9.7  0.7
This journal is © The Royal Society of Chemistry 2015
Fig. 3 In vivo time courses of PEG-SPIONs after intravenous injection
in Balb/c mice. (A) PEG1500-SPIONs; (B) PEG3000-SPIONs; (C)
PEG6000-SPIONs; (D) PEG8000-SPIONs; and (E) in vivo time courses
of Gadovist® after intravenous injection in Balb/c mice.
Fig. 4 Representative T2-weighted MR images of kidneys, liver and mu
PEG-1500 SPIONs. (A and F) T2-weighted images at 0 h; (B and G) at 1 h
Table 2 shows average T2 and DT2 values of the diﬀerent tissues.
This journal is © The Royal Society of Chemistry 2015
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View Article OnlineFTIR spectroscopy showed the presence of the PEG ligand on
the nanoparticle surface (Fig. S2†), and TGA analysis indicated a
percentage of PEGylate ligand around 40% for all PEG-SPIONs
(Fig. S3†). Moreover, the dispersant packing density of each
nanoparticle was calculated by TGA and TEM (Table 1). A
remarkable decreasing tendency of the number of molecules
per nm2 with the MW of PEG was observed from 1.99 molecules
per nm2, for the lowest MWs, to 0.35 molecules per nm2, for the
highest MWs. This tendency could be due to the steric
hindrance among the PEG ligands at the nanoparticle surface,
and also could explain the partial aggregation in the higher MW
PEG SPIONs.In vitro MR relaxivities of PEG-SPIONs
The relaxivity of the PEG-SPIONs weremeasured at low and high
magnetic elds. At clinical magnetic eld, 1.5 T, the
PEG-SPIONs showed transverse relaxivities, r2, of 90, 103, 190
and 180 mM1 s1 for PEG1500-, PEG3000-, PEG6000- and
PEG8000-SPIONs, respectively. This trend is in agreement with
the hydrodynamic diameter values. Since the inorganic core is
the same for all the nanoparticles, it was expected that the
transverse relaxivity, r2, would not change appreciably.
However, due to the partial aggregation induced by higher MW
PEGs, the transverse relaxivities increased considerably. This
eﬀect could aﬀect the in vivo results, giving rise to larger T2
contrast with less amount of nanoparticles or, mostscle at diﬀerent experimental times after the intravenous injection of
; (C and H) at 24 h; (D and I) at 48 h; (E and J) at 1 week after injection.
RSC Adv., 2015, 5, 76883–76891 | 76885
Fig. 5 Representative T2-weightedMR images of kidneys, liver andmuscle at diﬀerent experimental times after the intravenous injection of PEG-
3000 SPIONs. (A and F) T2-weighted images at 0 h; (B and G) at 1 h; (C and H) at 24 h; (D and I) at 48 h; (E and J) at 1 week after injection. Table 3
shows average T2 and DT2 values of the diﬀerent tissues.
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View Article Onlineimportantly, inducing a rapid clearance by the RES. The r2
measurements performed at high magnetic eld, 9.4 T, showed
the same trend found at low magnetic eld (114, 151, 253 to
254mM1 s1 for PEG1500-, PEG3000-, PEG6000- and PEG8000-
SPIONs, respectively).Stability of PEG-SPIONs
To demonstrate that the GA-PEG-OH ligands are well attached at
the nanoparticle surface conferring high stability to the
SPIONs,26–28 it was performed an exhaustive study by measuring
the hydrodynamic sizes of the PEG-SPIONs in diﬀerent solvents
and at diﬀerent concentrations, pH and temperatures. Fig. 1
shows the stability results using diﬀerent solvents: water, PBS
buﬀer and cell growth medium (DMEM + FBS + Medium 199), at
pH 7.2 and 37 C over 24 h, at concentration of 100 mg mL1 of
PEG-SPIONs. All the PEG-SPIONs presented constant hydrody-
namic sizes in the diﬀerent solvents except for the PEG600-
SPIONs in PBS buﬀer. As commented previously, the presence
of salts in the PBS buﬀer reduces the solubility of the nano-
particles leading to nanoparticle collapse. Intriguingly, this
eﬀect was not observed in the other solvent, cell growthmedium,
where the PEG600-SPIONs conserved similar hydrodynamic
sizes over 24 h, in spite of having similar salt concentrations.
This behavior could be due to the presence of other substances
that confer extra stability to the nanoparticles. An increment in
the concentration of PEG-SPIONs up to 500 mg mL1 (Fig. S4†)76886 | RSC Adv., 2015, 5, 76883–76891did not have an eﬀect on themeasured sizes, being similar to the
ones observed with a concentration of 100 mg mL1.
The stability of PEG at the surface of the nanoparticle was
also studied with respect to the temperature and the pH.
PEG1500-8000 SPIONs presented no change in their hydrody-
namic sizes up to 52 C in PBS buﬀer. PEG1500- and PEG3000-
SPIONs maintained constant sizes even up to 72 C. In contrast,
PEG6000 and PEG8000-SPIONs collapsed over 52 C probably
due to PEG cross-linking between the small aggregates favored
by high temperatures (Fig. 2A). As for the pH, all the
PEG-SPIONs remained with stable sizes from pH 7.4 to pH 5.3
(Fig. 2B), except for the PEG600-SPIONs, which collapsed
rapidly when the pH was lowered to 6.8 (data not shown).
Finally, the cytotoxicity was also evaluated by performing an
MTT assay at 24 h and 72 h of incubation (Fig. 2C and D). Both
time-lapse studies showed cell metabolic activities above 80% for
all the PEG-SPIONs from 0.1 mg mL1 to 100 mg mL1 of MNPs.
Summarizing, the stability studies showed the strong
attachment of the diﬀerent MW GA-PEG ligands to the nano-
particle surfaces, and the MTT assays showed no cytotoxicity
aer 24 h and 72 h of incubation. These results suggest high
biocompatibility for the PEG-SPIONs described herein and
support their potential use as in vivo contrast agents.
In vivo biodistributions of PEG-SPIONs
The semi-quantitative approach used to follow the pharmaco-
kinetics over the rst hour was carried out to study the rapidThis journal is © The Royal Society of Chemistry 2015
Fig. 6 Representative T2-weighted MR images of kidneys, liver and muscle at diﬀerent experimental times after the intravenous injection of
PEG-6000 SPIONs. (A and F) T2-weighted images at 0 h; (B and G) at 1 h; (C and H) at 24 h; (D and I) at 48 h; (E and J) at 1 week after injection.
Table 4 shows average T2 and DT2 values of the diﬀerent tissues.
Paper RSC Advances
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
1 
Se
pt
em
be
r 2
01
5.
 D
ow
nl
oa
de
d 
on
 0
4/
07
/2
01
6 
12
:0
2:
08
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlineuptake and excretion processes, which could have not been
tracked by using quantitative MRI, due to the low temporal
resolution of this type of measurements. Fig. 3 shows repre-
sentative pharmacokinetics of the PEGylated-SPIONs and gado-
butrol (gadolinium(III) 2,20,200-(10-((2R,3S)-1,3,4-trihydroxybutan-
2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate), which
have been used as a negative control for liver excretion and
positive control for renal excretion. It is well known that Gd-
complexones are not recognized by the RES and are rapidly
eliminated from the blood stream through the urine. Therefore,
we included experiments using one of these complexones for
comparison with the PEG-SPIONs commented above, which are
expected to be excreted through the liver and do not undergo
renal ltration.
Liver uptake
The RE curves (Fig. 3) show that all the PEG-SPIONs are readily
taken up by the liver where remain until the end of the experi-
ment. However, there are some important diﬀerences in the
uptake curves during the rst 10 min, with PEG1500- and
PEG3000-SPIONs showing slower uptake than PEG6000- and
PEG8000-SPIONs. PEG1500-SPIONs reached the maximal
concentration approximately 4 min aer injection, PEG3000-
SPIONs 2 minutes later, and PEG6000- and PEG8000-SPIONs
within the rst 2 min. This rapid liver uptake of both
PEG6000- and PEG8000-SPIONs could be related to the forma-
tion of aggregates commented above, which would beThis journal is © The Royal Society of Chemistry 2015immediately recognized by the RES. Interestingly, PEG1500-
SPIONs are taken up faster and reach higher concentrations
than PEG3000-SPIONs. Since PEG3000-SPIONs have a higher
relaxivity, we would expect higher RE values if both nano-
particles reach similar concentrations. However, the RE values
are noticeably higher for the PEG1500-SPIONs, indicating that
they reach signicantly higher concentration in the liver. This
behavior suggests that PEG1500-SPIONs have worse stealth
properties than PEG3000-SPIONs and hence they are more
avidly taken up by the liver.
Summing up, we can conclude that high MW PEGs (6000–
8000) lead to nanoparticle aggregation, and low MW PEGs
(#1500) are not able to stabilize the SPIONs in physiological
medium or confer stealth properties, thus leading to rapid
recognition by the RES. In contrast, PEG3000-SPIONs show
excellent in vivo behavior, they do not aggregate and exhibit
better stealth properties, being the best candidate for biomed-
ical applications in which long circulation times together with
moderate liver uptake are desirable.
Long-term pharmacokinetics (Fig. 4–7) showed that only
aer 1 week the PEGylated SPIONs were fully eliminated from
the liver. PEG1500-and PEG8000-SPIONs were eliminated faster,
showing around 80% T2 recovery at 48 h, whereas PEG6000-
SPIONs showed around 50% T2 recovery and PEG3000-SPIONs
only 35% (Fig. 8). This result is in agreement with PEG3000-
SPIONs having the longest blood circulation time, followed by
PEG6000 and nally PEG1500- and PEG8000-SPIONs.RSC Adv., 2015, 5, 76883–76891 | 76887
Fig. 7 Representative T2-weighted MR images of kidneys, liver and muscle at diﬀerent experimental times after the intravenous injection of
PEG-8000 SPIONs. (A and F) T2-weighted images at 0 h; (B and G) at 1 h; (C and H) at 24 h; (D and I) at 48 h; (E and J) at 1 week after injection.
Table 5 shows average T2 and DT2 values of the diﬀerent tissues.
Fig. 8 T2 recovery of the (A) liver and (B) kidneys after PEG-SPIONs
injections, where T2 recovery ð%Þ ¼

1 DT2ðtÞ
DT2ð0Þ

 100 .
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View Article OnlineRenal clearance and renal accumulation
Fig. 3E illustrates the renal excretion pharmacokinetics that
characterize small molecules, such as Gd-complexones. They
reach maximal concentrations in the kidneys very fast and then
rapidly decrease as they are being eliminated through the urine.
One hour aer injection, this type of contrast agents is practi-
cally fully cleared out from the bloodstream. On the contrary,
the PEGylated SPIONs accumulate in the kidneys (Fig. 3A–D and
S5†) because their HDs are well above the size exclusion limit
for glomerular ltration, which has been established in
6–8 nm.29 However, as already described by our group,28 the RE
increase observed in the bladder demonstrate that some
residual renal clearance also occurs. This phenomenon could
be explained by shrinkage or partial degradation of the organic
shell within the kidneys. In any case, it aﬀects to a very small76888 | RSC Adv., 2015, 5, 76883–76891fraction and therefore it should not have a signicant eﬀect on
the overall pharmacokinetics of PEGylated-SPIONs.
As for renal accumulation, it has been shown that PEGylated
NPs are retained in the corpuscles of the kidney cortex in a size-
dependent manner,30 with maximal retention for NPs with HD
diameters ranging from 76 to 96 nm, and no retention at all for
NPs with HD diameters below 25 nm, which could only be
found in the peritubular capillaries. According to this study,
PEG1500- and PEG3000-SPIONs (HDs 17 and 18 nm, respec-
tively) would not be retained at all, whereas PEG6000- and
PEG8000-SPIONs would only show partial retention (HDs 44 nm
and 46 nm) (Fig. S5†). Thus, because no retention is expected
for the small PEG-SPIONs (PEG1500- and PEG3000-), the signal
decay observed in the kidneys can only be attributed to the
circulating SPIONs, which shorten the T2 as they pass through
the peritubular blood capillaries. In other words, the signal
decay observed in the kidneys can be taken as an indicator of
the presence of PEG-SPIONs in the bloodstream when the HDs
are below 25 nm. According to this, PEG3000-SPIONs were only
partially clear out from the bloodstream aer one week,
showing just 50% T2 recovery in the kidneys (Fig. 8). They were
followed by PEG1500-SPIONs, with a 70% kidney T2 recovery. In
the case of PEG6000- and PEG8000-SPIONs the interpretation is
not so straightforward because part of the remaining signal
decay could be attributed to accumulation within the renal
corpuscles and not only to circulating nanoparticles.This journal is © The Royal Society of Chemistry 2015
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View Article OnlineIn summary, PEG3000-SPIONs seem to have the longest
circulation times, with signicant presence in the bloodstream
aer one week. Less amount of PEG1500-SPIONs was detected,
in agreement with the more eﬃcient elimination through the
liver observed for these SPIONs. Finally, the results obtained for
PEG6000- and PEG8000-SPIONs are less conclusive because of
the complexity underlying the signal T2 decay in the kidneys,
which involves both retained and circulating nanoparticles.
Conclusions
This study evidences interesting biodistribution diﬀerences
depending on the molecular weight and hydrodynamic diam-
eter of PEGylated iron oxide nanoparticles. An exhaustive
quantitative and semi-quantitative in vivo analysis was per-
formed on Balb/c mice by magnetic resonance imaging. On the
basis of these MRI analyses we demonstrate that PEG3000-
SPIONs exhibited the best in vivo behaviour with longer circu-
lation times and slower liver uptake. More in detail, it is
observed that PEG6000- and PEG8000-SPIONs reached the
maximal nanoparticle concentration in liver and kidneys
immediately aer injection, whereas the lower MW PEGs
reached the maximum aer 4 and 6 min (PEG1500- and
PEG3000-SPIONs, respectively). Long-term pharmacokinetics
showed that only aer one week PEGylated SPIONs were fully
eliminated from the liver, being PEG3000-SPIONs the ones
exhibiting the slower liver excretion, in agreement with
PEG3000-SPIONs having the longest circulation time. As
expected, PEG-SPIONs exhibited almost no renal excretion and
only very little amount was detected in the bladder. On the other
hand, the long-term follow up showed that even aer one week
there was a signicant T2 reduction, indicating that the SPIONs
were still present at that time. Because nanoparticles are only
retained in the corpuscles of the kidney cortex when their HDs
exceed 25 nm, the signal decay observed for PEG1500- and
PEG3000-SPIONs (HDs of 17 and 18 nm, respectively) can only
be attributed to circulating SPIONs, which shorten the T2 as
they pass through the peritubular blood capillaries. Therefore,
we can conclude that PEG3000-SPIONs were only partially clear
out from the bloodstream aer one week, showing just 50% T2
recovery in the kidneys, followed by PEG1500-SPIONs, with a
70% kidney T2 recovery. PEG6000-and PEG8000-SPIONs are
likely partially retained due to their higher hydrodynamic
diameter (HDs 44 nm and 46 nm respectively). In conclusion,
these studies show that, for small nanoparticles, with HDs
below 50 nm, a PEG coating of 3000 Da confers the best stealth
properties, resulting in longer circulation times and slower liver
uptake. The information provided by this type of studies can be
crucial for the rational design of new nanomaterials intended
for in vivo applications, such as molecular imaging or tumour
targeting.
Experimental
Materials
Reagents were obtained from commercial suppliers and used
without further purication. Iron(III) acetylacetonate, oleic acidThis journal is © The Royal Society of Chemistry 201599%, oleylamine, benzyl ether, 1,2-hexanedecanediol, gallic
acid, poly ethylene glycol 600 Da, 1500 Da, 3000 Da, 6000 Da and
8000 Da, triethylamine, 4-Dimethylaminopyridine, 3-[4,5-
dimethylthiazol-2yl]-2,5-diphenyltetrazolium bromide (MTT),
phosphate buﬀered saline (PBS), Dulbecco's Modied Eagle's
Medium (DMEM), Medium 199 and Foetal Calf Serum (FCS)
were supplied by Sigma Aldrich and Acros Organics. As solvents,
Milli-Q water (18.2 MU, ltered with lter pore size 0.22 mM)
from Millipore, toluene, isopropanol, ethanol, acetone, dime-
thylsulphoxide (DMSO), hexane, and anhydrous tetrahydro-
furan were used (HPLC grade, Acros Organics). Purication of
the water-soluble magnetic nanoparticles from free reagents
was performed using centrifuge lters PALL with a molecular
cut-oﬀ of 100 kDa. FTIR spectra were recorded with a FTIR-4100
Jasco.
Synthesis of 6 nm iron oxide nanoparticles (SPIONs)
Monodisperse 6 nm Fe3O4 nanoparticles were synthesized
following the protocol reported by Sun et al.31 Briey, 2 mmol of
iron acetylacetonate, 10 mmol of hexadecanediol, 6 mmol of
dodecylamine, 6 mmol of oleylamine and 20 mL of benzyl ether
were mixed andmagnetically stirred. The solution was heated to
200 C for 2 h under a ow of nitrogen, followed by temperature
increase to reux (300 C) for 1 h. The mixture was cooled down
to room temperature by removing the heating mantle. Finally,
the sample was washed several times using ethanol, acetone
and isopropanol as precipitation agents and centrifugation,
followed by re-dispersion in toluene.
Synthesis of gallol-derived PEGn-OH ligands (GA-PEGn-OH)
The GA-PEG(n ¼ 600, 1500, 3000, 6000 or 8000 Da)-OH ligands
were synthesized following the previously synthetic route
reported by Pellegrino and col.32 Briey, 1 mmol of
poly(ethylene glycol) (PEG) (Mw ¼ 600, 1500, 3000, 6000 or
8000 Da), 170 mg of gallic acid (1 mmol) and 23 mg of
4-dimethylaminopyridine (DMAP, 100 mmol) were dissolved in
100 mL of anhydrous THF in a round bottom ask under inert
atmosphere. A solution of dicyclohexil carbodiimide (DCC)
(1.01 g, 4.9 mmol, 20 mL THF) was added dropwise to the
mixture, and it was le stirred overnight at room temperature.
The solid urea formed was ltered out and the solvent was
removed in the rotaevaporator, yielding a crude GA-PEGn-OH.
The crude was dissolved in 100 mL of milli-Q water and
adjusted to pH 2. In a separation funnel, the GA-PEGn-OH was
extracted from the aqueous phase with diclomethane. The
organic phase was concentrated under reduced pressure,
yielding the corresponding GA-PEGn-OH. A solution of 0.1 M in
chloroform of GA-PEGn-OH ligand was prepared for the ligand
exchange procedures.
GA-PEG(n ¼ 600, 1500, 3000, 6000 or 8000 Da)-OH ligand
exchange on SPIONs
The 6 nm superparamagnetic iron oxide nanoparticles were
used as nanoparticle model for the diﬀerent PEGylated coating.
The PEGylation over the SPIONs was performed through a
ligand exchange protocol,26,27,32,33 where PEG moleculesRSC Adv., 2015, 5, 76883–76891 | 76889
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View Article Online(600, 1500, 3000 and 8000 Da) are attached covalently to a gallol
group to render Gallol-PEG-OH ligands. The diﬀerent molecular
weight ligands were exchanged for the capped surfactants
SPIONs thus leading to water soluble 600, 1500, 3000, 6000 and
8000 Da molecular weight PEGylated SPIONs (called from now
on PEG600-SPIONs, PEG1500-SPIONs, PEG3000-SPIONs,
PEG6000-SPIONs and PEG8000-SPIONs respectively). The
excess of the ligand was removed from the PEGylated SPIONs by
using the PALL centrifuge lters (MW cut-oﬀ: 100 kDa).
Transmission electron microscopy (TEM)
TEM images were obtained on a FEI Tecnai G2 Twinmicroscope
operated at an accelerating voltage of 100 kV. TEM samples were
prepared by dropping the solution on a carbon-coated copper
grid and letting the solvent evaporate.
Dynamic light scatering (DLS)
The size distribution and zeta potential measurements of the
GA-PEGn-OH were performed on a Zetasizer Nano ZS90
(Malvern, USA).
Thermogravimetric analysis (TGA)
Thermogravimetric analysis (TGA) was carried out by using a
METTLER TOLEDOmodel TGA/DSC 1 in the temperature range
30–800 C with a heating rate of a 10 C min1 under N2 ow
(50 mL min1).
ICP measurements
Fe concentrations were determined on an Inductively Coupled
Plasma High Resolution Mass Spectroscopy (ICP-HRMS,
Element XR, Thermo Fisher).
In vitro relaxivities
T2 relaxivities were calculated at two diﬀerent magnetic elds,
1.5 T (Bruker Minispec) and 9.4 T (Bruker Biospec) using
concentrations of GA-PEGn-OH SPIONs between 2.0 and
0.05 mM of Fe in physiological conditions, at 37 C. T2 was
determined using the Carl-Purcell-Meiboom-Gill (CPMG)
sequence.
Cytotoxicity assays
Briey, the MG-63 cells were plated at a density of 1  104 cells
per well in a 96-well plate at 37 C in 5% CO2 atmosphere
(200 mL per well, number of repetitions ¼ 5). Aer 24 h of
culture, the medium in the wells was replaced with fresh
medium containing PEG-SPIONs in varying concentrations
from 0.1 mg mL1 to 100 mg mL1. Aer 24 h (or 72 h), the
medium was removed and 200 mL of fresh medium with MTT
(0.5 mg mL1) was added to each well. Aer 2 h of incubation at
37 C and 5% CO2 the medium was removed and the formazan
crystals were solubilized with 200 mL of DMSO, and the solution
was vigorously mixed to dissolve the reacted dye. The absor-
bance of each well was read on a microplate reader (Dynatech
MR7000 instruments) at 550 nm. The relative cell viability (%)76890 | RSC Adv., 2015, 5, 76883–76891related to control wells containing cell culture medium without
nanoparticles was calculated by the equation:
Relative cell viability ð%Þ ¼ ½Abstest½Abscontrol 100
In vivo magnetic resonance imaging (MRI)
In vivo mice experiments were performed in accordance with
the ethical guidelines of Andalusian government. Female Balb/c
mice (n ¼ 3) with ca. 30 g in weight, provided by Janvier Labs
were used. Animals were anesthetized with 1% isourane, the
tail vein was cannulated and then the animals were placed in
the magnet, where respiration and body temperature were
monitored throughout the entire MRI experiment. The
GA-PEGn-OH SPIONs were administered intravenously via tail
vein at a concentration of 5 mg Fe per kg.
All the MRI experiments were carried out on a 9.4 T Bruker
Biospec system equipped with a 400 mT m1 gradients and a
40 mm quadrature bird-cage resonator. High resolution
T2-weighted images were acquired using a turbo-RARE
sequence with respiratory gating (TE ¼ 16 ms, TR ¼ 1000 ms,
4 averages, 156 mm in-plane resolution and 1 mm slice thick-
ness). Quantitative T2 measurements were also performed using
a multi-echo spin echo sequence (TEs ranging from 7 ms to
448 ms, TR ¼ 3500 ms, FOV ¼ 4 cm, matrix size ¼ 128  128,
slice thickness ¼ 1 mm). The time-courses were followed by
using a turbo-RARE sequence with the same parameters indi-
cated above, but only 1 average to improve temporal resolution
(1 image every 2 minutes). The acquisition scheme was as
follows: T2-weighted, quantitative T2, intravenous injection of
the GA-PEGn-OH SPIONs, time-course for one hour, quantita-
tive T2 and T2 weighted. The rst hour time courses were
analyzed semi-quantitatively using the following expression:
RE ¼
It  I0I0  100

where RE is the modulus of relative signal enhancement, It is
the signal intensity at any given time aer the nanoparticles
injection, and I0 is the signal intensity before the injection.
Long-term pharmacokinetics were measured by quantitative
T2 mapping at 0 h, 1 h, 24 h, 48 h and 1 week. Pharmacokinetics
were obtained by calculating the average values within diﬀerent
regions of interest (ROIs) placed on the following tissues: liver,
kidney, and muscle. Color-coded RE parametric maps were also
calculated on a pixel-by-pixel basis using in-house soware
written in IDL (RSI, Boulder, USA).Acknowledgements
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